Masahiro Yamawaki, Toshiya Muramatsu, Kazuhiro Ashida, Koichi Kishi, Yoshihiro Morino, Yoshihisa Kinoshita, Takashi Fujii, Yuichi Noguchi, Shingo Hosogi, Kazuya Kawai, Kiyoshi Hibi, Yoshisato Shibata, Hiroshi Ohira, Yasuhiro Morita, Yasuhiro Tarutani, Mikihito Toda, Yoshihisa Shimada, Yuji Ikari, Jiro Ando, Yutaka Hikichi, Yoritaka Otsuka, Yasushi Fuku, Shigenori Ito, Harumi Katoh, Kazushige Kadota, Yoshiaki Ito, Kazuaki Mitsudo
The appropriate stent platform for treating coronary bifurcation lesions (CBLs) remains controversial. Previous bench tests have demonstrated the superiority of a 2-link cell design to 3-link cell design for creating inter-strut dilation at the side branch ostium. This randomized multicenter prospective BEGIN trial compared the biodegradable polymer-based biolimus A9-eluting stent (2-link BES) with the durable polymer-based cobalt chromium everolimus-eluting stent (3-link EES) in 226 patients with de novo CBLs...
March 11, 2019: Heart and Vessels